Open AccessMHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease
Author(s) -
Julia SlottaHuspenina,
Kristina Schwamborn,
Katja Steiger,
Ricarda Simon,
Florian Kirchhoff,
Jakob Büchler,
Julia Fiedler,
Margitta Retz,
Roman Nawroth,
Christoph Ritschel,
Jürgen E. Gschwend,
Thomas Horn
Publication year - 2022
Publication title -
bladder cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.27
H-Index - 19
eISSN - 2352-3735
pISSN - 2352-3727
DOI - 10.3233/blc-211604
Subject(s) - metastatic urothelial carcinoma , cystectomy , medicine , major histocompatibility complex , immunotherapy , mhc class i , oncology , chemotherapy , cd8 , cohort , immunology , bladder cancer , immune system , cancer , urothelial carcinoma
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom